Lenoss Medical Inc
$61.1K 50 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Ovesco Endoscopy USA, Inc.
Ovesco Endoscopy USA, Inc. reported $60,991.83 across General Payments, Research, and Ownership to 62 physicians and teaching hospitals across 62 transactions.
- $61.0K Below-median payer
- All-tracks total
- 62 Below-median volume
- Transactions
- 62 Below-median reach
- Recipients
- +$12.8K
- General Payments vs PY2023
Ovesco Endoscopy USA, Inc. reported $60,991.83 across all CMS Open Payments tracks (General + Research + Ownership) to 62 physicians and teaching hospitals in Program Year 2024 - ranking #1304 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $60,991.83, averaging $983.74 per recipient.
Ovesco Endoscopy USA, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
17/100
Total payments
F
11/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ovesco-endoscopy-usa-inc Ovesco Endoscopy USA, Inc.
$61.0K · #1304/1,925 · 0.0% industry · PY2024
- TOT $61.0K
- RANK #1304
- SHARE 0.0%
- TXN 62
- RCP 62
- CAT 3
- GEN $61.0K
- ΔGEN +$12.8K
- TOP1 11.7%
- PY 2024
Volume peers
Nearest volume peer: Lenoss Medical Inc ($61.1K)
Ovesco Endoscopy USA, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Ovesco Endoscopy USA, Inc.'s CMS-reported General Payments increased by $12.8K (+26.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2023: OVESCO ENDOSCOPY USA, INC.PY2024: Ovesco Endoscopy USA, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $48,223.20
- PY2024
- $60,991.83
What the Data Shows for Ovesco Endoscopy USA, Inc.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Ovesco Endoscopy USA, Inc. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Travel and Lodging" at $41.6K, accounting for 68.2% of this company's General Payments and 52 transactions.
General Payment Breakdown by Type
Ovesco Endoscopy USA, Inc. made 3 types of general payments. "Travel and Lodging" is the largest category at $41.6K, 68.2% of General Payments.
How Ovesco Endoscopy USA, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Travel and Lodging | $41.6K | 52 | 68.2% |
| Consulting Fee | $19.2K | 9 | 31.5% |
| Food and Beverage | $153.63 | 1 | 0.3% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $21,804.42 (35.7%) of $60,991.83 in this company's General Payments records across 56 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Ovesco Endoscopy USA, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Jianhua Tau
$7,120.16 across 1 reported transactions
- 2
Phillip Ge
$4,725.00 across 5 reported transactions
- 3
Bhavesh Shah
$4,676.75 across 1 reported transactions
- 4
Jerome Edelson
$2,832.51 across 3 reported transactions
- 5
Jason Samarasena
$2,450.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Ovesco Endoscopy USA, Inc.'s spend rank (#1304 of 1,925, bottom 32% by spend) and concentration rank (#1,386 of 1,838, bottom 25% least concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Phadia US Inc. : $290.0K total payments, HHI 390
- Sonendo Inc : $1.3M total payments, HHI 386
- Astellas Pharma Global Development : $662.0K total payments, HHI 386
- Breg, Inc : $959.96 total payments, HHI 385
- Impulse Dynamics (USA) Inc. : $1.3M total payments, HHI 385
- Medela LLC : $63.1K total payments, HHI 384
- Ovesco Endoscopy USA, Inc. (this company) : $61.0K total payments, HHI 384
- Augmedics Inc. : $233.7K total payments, HHI 383
- Daiichi Sankyo Inc. : $6.9M total payments, HHI 382
- Biocomposites Inc : $138.8K total payments, HHI 381
- Dental Health Products, Inc. : $7.5K total payments, HHI 380
- XVIVO Perfusion Inc. : $51.8K total payments, HHI 377
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Ovesco Endoscopy USA, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ovesco Endoscopy USA, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Ovesco Endoscopy USA, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Vertical Pharmaceuticals, LLC
$60.9K 2,949 recipients
Compare payment profiles
Forma Medical
$61.1K 76 recipients
Compare payment profiles
Perrigo Company plc
$60.8K 12 recipients
Compare payment profiles
Clarius Mobile Health Corp.
$60.4K 27 recipients
Compare payment profiles
Kowa Research Institute, Inc.
$61.6K 101 recipients
Compare payment profiles
Put this to use
Ovesco Endoscopy USA, Inc. ranks #1304 of 1,925 by all-tracks total payments, led by "Travel and Lodging".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Travel and Lodging" spend across every manufacturer, not just Ovesco Endoscopy USA, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.